Imcera
This article was originally published in The Gray Sheet
Executive Summary
Mallinckrodt parent expects to record a pretax restructuring charge of about $325 mil. in the fourth quarter (ending June 30). The restructuring will take about two years to complete and will focus primarily on the Northbrook, Illinois-based firm's ailing Pitman-Moore animal health care unit. The firm announced in March that it expected to take a "significant restructuring charge" ("The Gray Sheet" March 29, p. 13).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.